Does short-segment columnar-lined esophagus elongate during a mean follow-up period of 5.7 years?

Digestive Endoscopy

Volumn 23, Issue 2, 2011, Pages 166-172

  Manabe, Noriaki ^a   Haruma, Ken ^a   Imamura, Hiroshi ^a   Kamada, Tomoari ^a   Kusunoki, Hiroaki ^a   Inoue, Kazuhiko ^a   Shiotani, Akiko ^a   Hata, Jiro ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

atrophic gastritis; Barrett's esophagus; esophagitis; hiatal hernia

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHRONOLOGY; CONTROLLED STUDY; ENDOSCOPY; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; SHORT SEGMENT COLUMNAR LINED ESOPHAGUS;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; FEMALE; GASTRITIS, ATROPHIC; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PRECANCEROUS CONDITIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 79953061636     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2010.01073.x     Document Type: Article

References (49)

1. Haggitt RC,. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum. Pathol. 1994; 25: 982-93. (Pubitemid 24313642)
2. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS,. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8. (Pubitemid 30621983)
3. Cameron AJ,. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis. Esophagus. 2002; 15: 106-8. (Pubitemid 35264630)
4. Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R,. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 2007; 109: 668-74. (Pubitemid 46233227)
5. Weston AP, Sharma P, Mathur S, et al,. Risk stratification of Barrett's esophagus: Updated prospective multivariate analysis. Am. J. Gastroenterol. 2004; 99: 1657-66. (Pubitemid 39237488)
6. Eisen GM, Sandler RS, Murray S, Gottfried M,. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 27-31. (Pubitemid 27027023)
7. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M,. Length of Barrett oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
8. Gopal DV, Lieberman DA, Magaret N, et al,. Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from a multicenter consortium. Dig. Dis. Sci. 2003; 48: 1537-41. (Pubitemid 36936690)
9. Hirota WK, Loughney TM, Lazas DJ, Mayudonovitch CL, Rholl V, Wong RK,. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data. Gastroenterology 1999; 116: 277-85. (Pubitemid 29055349)
10. Weston AP, Badr AS, Hassanein RS,. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 1999; 94: 3413-9.
11. Hoshihara Y, Kogure T, Yamamoto T, et al,. Diagnosis of short segment Barrett's esophagus. Stom. Intest. 1999; 34: 133-9.
12. Aoki T, Kawamura Y, Kouzu T,. Definition of Barrett Esophagus (Epithelium). Report of Japan Esophageal Society 2000; 20-3. (in Japanese.)
13. Armstrong D, Bennett JR, Blum AL, et al,. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996; 111: 85-92. (Pubitemid 26226887)
14. Kimura K, Takemoto T,. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87-97.
15. Yamagishi H, Koike T, Ohara S, et al,. Tongue-like Barrett's esophagus is associated with gastroesophageal reflux disease. World J. Gastroenterol. 2008; 14: 4196-203.
16. Cameron A, Lomboy C,. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
17. Lagergren J, Bergstrom R, Lindgren A, Nyren O,. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999; 340: 825-31. (Pubitemid 29142625)
18. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ,. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig. Dis. Sci. 2002; 47: 256-64. (Pubitemid 34123982)
19. Dickman R, Green C, Chey WD, et al,. Clinical predictors of Barrett's esophagus length. Gastrointest. Endosc. 2005; 62: 675-81. (Pubitemid 41502990)
20. Jones MP, Sloan SS, Rabine JC, Ebert CC, Kahrilas PJ,. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am. J. Gastroenterol. 2001; 96: 1711-7.
21. Okita K, Amano Y, Takahashi Y, et al,. Barrett's esophagus in Japanese patients: Its prevalence, form, and elongation. J. Gastroenterol. 2008; 43: 928-34.
22. Nandurkar S, Talley NJ,. Barrett's esophagus: The long and short of it. Am. J. Gastroenterol. 1999; 94: 30-40.
23. Falk GW,. Reflux disease and Barrett's esophagus. Endoscopy 1999; 31: 9-16. (Pubitemid 29092371)
24. Peters FT, Ganesh S, Kuipers EJ, et al,. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomized double blind study. Gut 1999; 45: 489-94. (Pubitemid 29447813)
25. Sharma P, Sampliner RE, Camargo E,. Normalization of esophageal pH with high-dose proton pump inhibitor therapy dose not result in regression of Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 582-5. (Pubitemid 27184368)
26. Gore S, Healey CJ, Sutton R, et al,. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment. Pharmacol. Ther. 1993; 7: 623-8. (Pubitemid 24035172)
27. Cooper BT, Neumann CS, Cox MA, Iqbal TH,. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment. Pharmacol. Ther. 1998; 12: 893-7. (Pubitemid 28428955)
28. Gatenby PA, Caygill CP, Ramus JR, Charlett A, Fitzgerald RC, Watson A,. Short segment columnar-lined oesophagus: An underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur. J. Gastroenterol. Hepatol. 2007; 19: 969-75. (Pubitemid 350287403)
29. de Mas CR, Kramer M, Seifert E, Rippin G, Vieth M, Stole M,. Short Barrett: Prevalence and risk factors. Scand. J. Gastroenterol. 1999; 34: 1065-70. (Pubitemid 29533762)
30. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M,. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 407-13. (Pubitemid 27108171)
31. Yagi K, Nakamura A, Sekine A, Tamiya Y, Oyamatsu M, Watanabe E,. Endoscopic findings of adenocarcinoma arising from short-segment Barrett's esophagus. J. Gastroenterol. Hepatol. 2004; 19: 940-43. (Pubitemid 39093218)
32. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R,. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am. J. Gastroenterol. 2006; 101: 1900-20.
33. Ishimura N, Amano Y, Kinoshita Y,. Endoscopic definition of esophagogastric junction for diagnosis of Barrett's esophagus: Importance of systematic education and training. Dig. Endosc. 2009; 21: 213-8.
34. Vianna A, Hayes PC, Moscoso G, et al,. Normal venous circulation of the gastroesophageal junction. A route to understanding varices. Gastroenterology 1987; 93: 876-89. (Pubitemid 17156016)
35. Hoshihara Y, Kogure T, Yamamoto T, et al,. Endoscopic diagnosis of Barrett's esophagus. Nippon Rinsho 2005; 63: 1394-8. (in Japanese.)
36. Aoki T, Hanyu N, Mukai H,. Gastroesophageal reflux disease and Barrett's esophagus: Inspection in Japan. Sogo Rinsho 2005; 63: 2005-8. (in Japanese.)
37. Wang KK, Sampliner RE,. Practice parameters committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2008; 103: 788-97. (Pubitemid 351406009)
38. Odze RD,. Unraveling the mystery of the gastroesophageal junction: A pathologist's perspective. Am. J. Gastroenterol. 2005; 100: 1853-67. (Pubitemid 41648443)
39. Phillips RW, Frierson HF, Moskaluk CA,. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am. J. Surg. Pathol. 2003; 27: 1442-7. (Pubitemid 37315196)
40. Chu PG, Ishizawa S, Wu E, Weiss LM,. Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to CEA, CD10 and AFP. Am. J. Surg. Pathol. 2002; 26: 978-88. (Pubitemid 34810558)
41. Freund JN, Domon-Dell C, Kedinger M, Duluc I,. Cdx1 and Cdx2 homeobox genes in the intestine. Biochem. Cell Biol. 1998; 7: 957-69. (Pubitemid 29450564)
42. Glickman JN, Shahsafaei A, Odze RD,. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am. J. Surg. Pathol. 2003; 27: 1357-65. (Pubitemid 37185827)
43. Cameron AJ, Souto EO, Smyrk TC,. Small adenocarcinomas of the esophagogastric junction: Association with intestinal metaplasia and dysplasia. Am. J. Gastroenterol. 2002; 97: 1375-80. (Pubitemid 34664780)
44. Cabrera RA, Chaves P, Crespo M, et al,. Adenocarcinoma of the esophagogastric junction: Could the characteristics of adjacent intestinal metaplasia help in the understanding of biopathogenesis. Dis. Esophagus 2002; 15: 287-9. (Pubitemid 36149772)
45. El-Serag HB, Garewel H, Kuebeler M, Sampliner RE,. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin. Gastroenterol. Hepatol. 2004; 2: 296-300. (Pubitemid 38447193)
46. Amano Y, Ishimura N, Furuta K, et al,. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest. Endosc. 2006; 64: 206-11. (Pubitemid 44081905)
47. Chak A, Lee T, Kinnard MF, et al,. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002; 51: 323-8.
48. Stein DJ, Sl-Serag HB, Kuczynski J, et al,. The association of body mass index with Barrett's oesophagus. Aliment. Pharmacol. Ther. 2005; 22: 1005-10. (Pubitemid 41634883)
49. Watanabe S, Hojo M, Nagahara A,. Metabolic syndrome and gastrointestinal diseases. J. Gastroenterol. 2007; 42: 267-74. (Pubitemid 46681700)